SCHEDULE: Janus Henderson Amends Madrigal Pharma Stake to 8.3%
Beneficial Ownership Amendment
Janus Henderson Group plc has filed an amendment to its beneficial ownership in Madrigal Pharmaceuticals, Inc., reporting an 8.3% stake in the company's common stock.
Summary
- Janus Henderson Group plc reported beneficial ownership of 1,842,690 shares of Madrigal Pharmaceuticals, Inc. common stock.
- This ownership represents 8.3% of the class of securities.
- The filing is an Amendment No. 7 to a Schedule 13G, indicating a change from previous disclosures.
- Janus Henderson Group plc, through its indirect subsidiaries JHIUS, JHIUKL, and JHIAIFML, acts as an investment adviser to Managed Portfolios.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a standard amendment to beneficial ownership, reporting an institutional stake. It does not contain information that would inherently be positive or negative for the issuer's performance or outlook.
Future Outlook
NA
Industry Context
Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's stock, indicating a passive investment intent. This filing shows continued significant institutional interest in Madrigal Pharmaceuticals by Janus Henderson, a major asset manager.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure Requirement | The filing itself is a corporate governance requirement for transparency of significant ownership stakes by institutional investors, ensuring public awareness of major shareholders. | 11/14/2025 | Enhances transparency for shareholders and the market regarding institutional holdings. |
Stakeholder Impact
- Shareholders: Provides transparency on a significant institutional holder's stake, which can influence market perception.
- Investment Community: Offers insight into institutional investment trends and confidence in Madrigal Pharmaceuticals.
Key Dates
| Date | Description |
|---|---|
| 12/09/2022 | Date Power of Attorney was executed by Janus Henderson Group plc. |
| 09/30/2025 | Date of event which requires filing of this statement. |
| 11/14/2025 | Date of signature for the Schedule 13G filing. |
Keywords
Madrigal Pharmaceuticals, Janus Henderson, Schedule 13G, beneficial ownership, common stock, institutional investment, pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.